open access

Vol 12, No 2 (2007)
Untitled
Published online: 2007-03-01
Submitted: 2006-09-14
Get Citation

Intraluminal pulsed dose rate (PDR) brachytherapy and trans-hepatic technique in treatment of locally advanced bile duct cancer – preliminary assessment

Janusz Skowronek, Aleksander Sowier, Paweł Skrzywanek
DOI: 10.1016/S1507-1367(10)60049-1
·
Rep Pract Oncol Radiother 2007;12(2):125-133.

open access

Vol 12, No 2 (2007)
Untitled
Published online: 2007-03-01
Submitted: 2006-09-14

Abstract

Background

Treatment options for bile duct cancer remain limited due to the large number of patients with advanced disease at the time of diagnosis. Radical surgery is possible in less than 10–15% of these cases. Unresectable bile duct cancers are very difficult to treat with external beam therapy alone due to the proximity of adjacent normal organs and the high doses required to effectively irradiate these neoplasms. Indications for brachytherapy include all malignant strictures of the bile duct which can be cannulated. Patients should be fit enough for the procedure and should have been reviewed to confirm that they are not suitable for resection. Combined treatment is possible in patients who are in good condition; it is usual to combine bile duct brachytherapy (BT) with external beam radiation therapy (EBRT).

Aim

To assess the feasibility of intraluminal palliative pulsed dose rate brachytherapy (PDR-BT) in the treatment of locally advanced bile duct cancer.

Materials/Methods

Seventeen patients with advanced inoperable bile duct cancer were treated between May 2002 and December 2005 in Greatpoland Cancer Centre. Patients were disqualified from surgery or radical external beam radiation therapy (EBRT). Thirteen patients were treated exclusively with PDR brachytherapy, 4 patients were qualified for combined treatment: PDR brachytherapy and palliative EBRT. Percutaneous trans-hepatic technique was used to implant a catheter into the bile duct. All patients received 25 pulses of 0.8Gy hourly to the total dose of 20Gy. In 4 cases PDR was repeated after one week. Target Volume encompassed tumour visualized at cholangiography and a one or two cm margin taken proximally and distally. Dose was prescribed at 10mm from the source axis. For palliative EBRT 15MV photons were used.

Results

In all 17 cases trans-hepatic technique allowed insertion of the BT catheter into the bile duct and safe application of PDR-BT. In 13/17 (76.5%) cases improvement in jaundice was noted at the first check-up after 4 weeks. Median overall survival time (OS) was 10 months, longest survival time was 36 months, shortest was 2 months. Acute and late complications were not observed.

Conclusions

1. It was established that the use of pulsed dose rate brachytherapy was feasible and had a low early complication rate. A new percutaneous trans-hepatic technique allowed whole treatment (insertion of catheter, PDR brachytherapy) to be performed in one day. 2. In most cases a satisfactory palliative effect was achieved.

Abstract

Background

Treatment options for bile duct cancer remain limited due to the large number of patients with advanced disease at the time of diagnosis. Radical surgery is possible in less than 10–15% of these cases. Unresectable bile duct cancers are very difficult to treat with external beam therapy alone due to the proximity of adjacent normal organs and the high doses required to effectively irradiate these neoplasms. Indications for brachytherapy include all malignant strictures of the bile duct which can be cannulated. Patients should be fit enough for the procedure and should have been reviewed to confirm that they are not suitable for resection. Combined treatment is possible in patients who are in good condition; it is usual to combine bile duct brachytherapy (BT) with external beam radiation therapy (EBRT).

Aim

To assess the feasibility of intraluminal palliative pulsed dose rate brachytherapy (PDR-BT) in the treatment of locally advanced bile duct cancer.

Materials/Methods

Seventeen patients with advanced inoperable bile duct cancer were treated between May 2002 and December 2005 in Greatpoland Cancer Centre. Patients were disqualified from surgery or radical external beam radiation therapy (EBRT). Thirteen patients were treated exclusively with PDR brachytherapy, 4 patients were qualified for combined treatment: PDR brachytherapy and palliative EBRT. Percutaneous trans-hepatic technique was used to implant a catheter into the bile duct. All patients received 25 pulses of 0.8Gy hourly to the total dose of 20Gy. In 4 cases PDR was repeated after one week. Target Volume encompassed tumour visualized at cholangiography and a one or two cm margin taken proximally and distally. Dose was prescribed at 10mm from the source axis. For palliative EBRT 15MV photons were used.

Results

In all 17 cases trans-hepatic technique allowed insertion of the BT catheter into the bile duct and safe application of PDR-BT. In 13/17 (76.5%) cases improvement in jaundice was noted at the first check-up after 4 weeks. Median overall survival time (OS) was 10 months, longest survival time was 36 months, shortest was 2 months. Acute and late complications were not observed.

Conclusions

1. It was established that the use of pulsed dose rate brachytherapy was feasible and had a low early complication rate. A new percutaneous trans-hepatic technique allowed whole treatment (insertion of catheter, PDR brachytherapy) to be performed in one day. 2. In most cases a satisfactory palliative effect was achieved.

Get Citation

Keywords

bile duct cancer; palliative; PDR brachytherapy; radiotherapy

About this article
Title

Intraluminal pulsed dose rate (PDR) brachytherapy and trans-hepatic technique in treatment of locally advanced bile duct cancer – preliminary assessment

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 12, No 2 (2007)

Pages

125-133

Published online

2007-03-01

DOI

10.1016/S1507-1367(10)60049-1

Bibliographic record

Rep Pract Oncol Radiother 2007;12(2):125-133.

Keywords

bile duct cancer
palliative
PDR brachytherapy
radiotherapy

Authors

Janusz Skowronek
Aleksander Sowier
Paweł Skrzywanek

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl